Lycia Therapeutics director receives two option awards

The awards have different service-based vesting conditions: one vests monthly over four years, while the other vests fully on October 22, 2027.

Rhea-AI Filing Summary

Lycia Therapeutics, Inc. director William Jl Rieflin acquired two stock-option awards covering 24,840 shares and 20,000 shares. The August 11, 2026 award has a $3.70 exercise price and vests monthly at 1/48 of the award over four years, with the first tranche vested September 6, 2026, subject to service on each vesting date. The October 22, 2026 award has an $18 exercise price and vests 100% on October 22, 2027, subject to service on that date. The August award occurred before Lycia's registration of a class of equity securities under Section 12 of the Exchange Act in connection with its initial public offering and was reported pursuant to Rule 16a-2(a).

Insider Trade Summary

Grant/Award: 44,840 shares

Grant/Award 2 txns

Insider RIEFLIN WILLIAM JL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F3	20,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) F1, F2	24,840	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 44,840 contracts (Direct)

Footnotes (3)

1. F1. The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
2. F2. The options vest as to 1/48 of the total award monthly over four years, with the first tranche vested on September 6, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
3. F3. The options will vest as to 100% of the award on October 22, 2027, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Key Figures

Option award: 24,840 underlying shares Exercise price: $3.70 per share Option expiration: August 10, 2036 +3 more

6 metrics

Option award 24,840 underlying shares Award dated August 11, 2026

Exercise price $3.70 per share Option award dated August 11, 2026

Option expiration August 10, 2036 Option award dated August 11, 2026

Option award 20,000 underlying shares Award dated October 22, 2026

Exercise price $18 per share Option award dated October 22, 2026

Option expiration October 21, 2036 Option award dated October 22, 2026

Key Terms

Stock Option (Right to Buy), Rule 16a-2(a), Section 12 of the Exchange Act

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

Rule 16a-2(a) regulatory

"reported herein pursuant to Rule 16a-2(a)"

Section 12 of the Exchange Act regulatory

"registration of a class of equity securities under Section 12 of the Exchange Act"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What option awards did LYCA director William Jl Rieflin receive?

LYCA director William Jl Rieflin received an option covering 24,840 shares on August 11, 2026, with a $3.70 exercise price, and an option covering 20,000 shares on October 22, 2026, with an $18 exercise price. The first vests monthly over four years; the second vests 100% on October 22, 2027, subject to service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/26/2026 - 08:21 PM EDT Accepted by SEC EDGAR 10/26/2026 - 07:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RIEFLIN WILLIAM JL

(Last) (First) (Middle)

C/O LYCIA THERAPEUTICS, INC.

400 EAST JAMIE COURT, SUITE 200

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.7	08/11/2026(1)		A		24,840		(2)	08/10/2036	Common Stock	24,840	$0	24,840	D
Stock Option (Right to Buy)	$18	10/22/2026		A		20,000		(3)	10/21/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).

2. The options vest as to 1/48 of the total award monthly over four years, with the first tranche vested on September 6, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

3. The options will vest as to 100% of the award on October 22, 2027, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

	/s/ Amy Bachrodt, Attorney-in-Fact	10/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)